Une Y, Nagabuchi E, Ogasawara K, Kamiyama T, Saito M, Gotoda A, Sato N, Nakajima Y, Uchino J
1st Dept. of Surgery, Hokkaido University School of Medicine.
Gan To Kagaku Ryoho. 1991 Jun;18(7):1195-8.
Four cases of advanced hepatocellular carcinoma patients were treated by intra-portal infusion of 5-FU immediately after surgery. 5-FU at 120-250 mg daily was injected continuously via portal catheter from postoperative day 4 to 21. Two cases with short administration period of 4 days died of recurrence on the residual liver at 9 and 7 months after hepatic resection. Another 2 cases with a total amount of 5-FU at 2,165 mg and 2,250 mg, respectively, survived 4 years 3 months and 4 year 8 months each. Mild leukocytopenia and transient liver dysfunction were found as side effects. Intraportal infusion of anticancer drugs is a promising means to prevent intrahepatic micrometastasis after resection of hepatocellular carcinoma.
4例晚期肝细胞癌患者在手术后立即通过门静脉输注5-氟尿嘧啶进行治疗。从术后第4天至第21天,每天通过门静脉导管连续注射120-250mg的5-氟尿嘧啶。给药期短至4天的2例患者在肝切除术后9个月和7个月死于残留肝脏的复发。另外2例患者分别接受总量为2165mg和2250mg的5-氟尿嘧啶治疗,分别存活了4年3个月和4年8个月。发现有轻度白细胞减少和短暂肝功能障碍等副作用。门静脉内输注抗癌药物是预防肝细胞癌切除术后肝内微转移的一种有前景的方法。